What you said should actually belong to angiotensin converting enzyme inhibitors (angiotensin converting enzyme inhibitors; ACE inhibitor; ACEI) was first developed and listed by Bristol-Myers Squibb Company in 198 1. Judging from its molecular structure, it belongs to the derivative of proline. The name (that is, ending in -pril) follows the stem used by the international common name (INN) and comes from proline.
The letter I of ACEI is the abbreviation of inhibitors, ACEI refers to crushed drugs, and ACE 1 is angiotensin 1 produced in human body, which is converted into ACE2 by angiotensin converting enzyme and then acts. ACEI and ACE 1 are existential words, which are easy to be confused.